Date: 2017-02-13
Type of information: Initiation of preclinical development
phase: 1
Announcement: initiation of the trial
Company: Bayer (Germany)
Product: BAY1834845
Action mechanism:
Disease: pelvic inflammatory disease
Therapeutic area: Inflammatory diseases
Country: Germany
Trial
details: This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics and explore the pharmacodynamics of ascending single doses of BAY1834845 using a placebo controlled, randomized, single center design. (NCT03054402)
Latest
news: * On February 13, 2017, a Phase 1 trial sponsored by Bayer was published on the NIH website ClinicalTrials.gov for BAY1834845.
